TOP TEN perturbations for 39823_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39823_at
Selected probe(set): 238340_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39823_at (238340_at) across 6674 perturbations tested by GENEVESTIGATOR:
psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; non-responder) / psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; non-responder)
Relative Expression (log2-ratio):-1.2853775Number of Samples:9 / 2
Experimental | psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; non-responder) |
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 90 mg ustekinumab and assigned as non-responders. Ustekinumab was administered subcutaneously in dose of 90 mg at week 0 and 4. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code: | |
Control | psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; non-responder) |
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 45 mg ustekinumab and assigned as non-responders. Ustekinumab was administered subcutaneously in dose of 45 mg at week 0 and 4. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code: |
cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue
Relative Expression (log2-ratio):-1.2692833Number of Samples:4 / 8
Experimental | cutaneous T-cell lymphoma study 1 (tumor phase) |
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal). | |
Control | normal skin tissue |
Skin biopsies from healthy individuals. |
psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; responder) / psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; non-responder)
Relative Expression (log2-ratio):-1.1646109Number of Samples:16 / 2
Experimental | psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; responder) |
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 45 mg ustekinumab and assigned as responders. Ustekinumab was administered subcutaneously in dose of 45 mg at week 0 and 4. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code: | |
Control | psoriasis study 24 (lesional; ustekinumab; 12wk; 45mg; non-responder) |
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 45 mg ustekinumab and assigned as non-responders. Ustekinumab was administered subcutaneously in dose of 45 mg at week 0 and 4. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code: |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-1.0345249Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
dengue fever study 10 (DHF) / normal naive CD8 T cell sample
Relative Expression (log2-ratio):-1.0114756Number of Samples:2 / 5
Experimental | dengue fever study 10 (DHF) |
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue hemorrhagic fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, HLA_DR+, and CD38+ effector CD8 T subtype cells were used for analysis. | |
Control | normal naive CD8 T cell sample |
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis. |
cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue
Relative Expression (log2-ratio):-0.98404884Number of Samples:7 / 8
Experimental | cutaneous T-cell lymphoma study 1 (plaque phase) |
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase. | |
Control | normal skin tissue |
Skin biopsies from healthy individuals. |
engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)
Relative Expression (log2-ratio):0.96621704Number of Samples:6 / 3
Experimental | engineered skin substitute study 2 (intermediate) |
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice. | |
Control | engineered skin substitute study 1 (intermediate) |
Human skin substitutes tissue samples collected after 7 days in culture. |
pediatric septic shock study 3 (toddler; subclass A) / pediatric septic shock study 3 (toddler)
Relative Expression (log2-ratio):0.9585829Number of Samples:4 / 23
Experimental | pediatric septic shock study 3 (toddler; subclass A) |
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses. | |
Control | pediatric septic shock study 3 (toddler) |
Whole blood obtained from toddlers (2 – 5 years) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Two children did not survive. |
medulloblastoma study 2 / non-tumor brain tissue
Relative Expression (log2-ratio):0.9399805Number of Samples:4 / 9
Experimental | medulloblastoma study 2 |
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma. | |
Control | non-tumor brain tissue |
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):-0.9372511Number of Samples:3 / 3
Experimental | influenza virus study 10 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
Organism: Homo sapiens
Gene: 39823_at
Selected probe(set): 202250_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39823_at (202250_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary)
Relative Expression (log2-ratio):-2.632474Number of Samples:2 / 4
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (endometrioid and papillary serous adenocarcinoma; primary) |
Primary tumor tissue samples obtained from the ovary of patients with endometrioid and papillary serous adenocarcinoma. |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.5890083Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.3899918Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.3621693Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (mixed epithelial tumor; primary)
Relative Expression (log2-ratio):-2.1857128Number of Samples:2 / 3
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (mixed epithelial tumor; primary) |
Primary tumor tissue samples obtained from the ovary of patients with mixed epithelial tumor. |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.1651182Number of Samples:3 / 3
Experimental | influenza virus study 11 (A/H5N3) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) / expO ovary cancer study 1 (carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.0641336Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (transitional cell carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with transitional cell carcinoma (NOS). | |
Control | expO ovary cancer study 1 (carcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the ovary of patients with carcinoma (NOS). |
stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):2.0260725Number of Samples:3 / 4
Experimental | stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):1.9993935Number of Samples:3 / 3
Experimental | influenza virus study 10 (A/H5N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)
Relative Expression (log2-ratio):1.947298Number of Samples:2 / 8
Experimental | male infertility study 1 (juvenile; Ad-) |
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells. | |
Control | normal testicular lobules tissue (mJS10) |
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10). |